Myovant Sciences (NYSE:MYOV – Get Rating) and Precigen (NASDAQ:PGEN – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.
Risk and Volatility
Myovant Sciences has a beta of 2.78, suggesting that its stock price is 178% more volatile than the S&P 500. Comparatively, Precigen has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Myovant Sciences and Precigen, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Myovant Sciences currently has a consensus target price of $16.67, indicating a potential upside of 21.04%. Precigen has a consensus target price of $11.50, indicating a potential upside of 721.43%. Given Precigen’s stronger consensus rating and higher possible upside, analysts plainly believe Precigen is more favorable than Myovant Sciences.
Earnings and Valuation
This table compares Myovant Sciences and Precigen’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Myovant Sciences||$230.97 million||5.68||-$205.98 million||($2.21)||-6.23|
|Precigen||$103.87 million||2.80||-$92.17 million||($0.48)||-2.92|
Precigen has lower revenue, but higher earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
32.6% of Myovant Sciences shares are owned by institutional investors. Comparatively, 78.2% of Precigen shares are owned by institutional investors. 5.1% of Myovant Sciences shares are owned by insiders. Comparatively, 42.7% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Myovant Sciences and Precigen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Precigen beats Myovant Sciences on 10 of the 14 factors compared between the two stocks.
About Myovant Sciences (Get Rating)
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
About Precigen (Get Rating)
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.